# APOA5

## Overview
The APOA5 gene encodes apolipoprotein A5, a critical component in lipid metabolism, particularly in the regulation of plasma triglyceride levels. This gene is located on chromosome 11q23 within the ApoA1-ApoC3-ApoA4 gene cluster and is primarily expressed in the liver (Alborn2006Definitive). The protein product, apolipoprotein A5, is a lipid-binding protein that plays a significant role in modulating triglyceride levels by enhancing the catabolism of triglyceride-rich lipoproteins and inhibiting the production of very low-density lipoprotein (VLDL) (Garelnabi2013The). Apolipoprotein A5 interacts with lipoprotein lipase (LPL) and other proteins to facilitate triglyceride hydrolysis, thereby maintaining lipid homeostasis (Schaap2004ApoAV). Mutations in the APOA5 gene are associated with disorders such as hypertriglyceridemia and chylomicronemia, underscoring its clinical significance in cardiovascular health (Soufi2012Mutation; Dussaillant2012APOA5).

## Structure
Apolipoprotein A5 (APOA5) is a protein involved in lipid metabolism, primarily influencing triglyceride levels. The primary structure of APOA5 consists of a sequence of amino acids encoded by the APOA5 gene, located in the ApoA1-ApoC3-ApoA4 gene cluster on human chromosome 11q23 (Alborn2006Definitive). The mature protein has a predicted relative molecular mass of 39,000 and contains a single cysteine residue, circulating mainly as a monomer in plasma (Alborn2006Definitive).

The secondary structure of APOA5 is characterized by a helical structure, with α-helicity increasing from 37% in acidic conditions to 56% in neutral conditions, indicating structural adaptation in physiological conditions (Castleberry2020Functional). This helical structure is crucial for its function in lipid interaction and metabolism.

APOA5 can form multiple oligomeric species in solution, existing as multimers in dynamic equilibrium, similar to APOA1 (Castleberry2020Functional). This suggests a level of quaternary structure where APOA5 interacts with other molecules, although specific details on its tertiary and quaternary structures are not provided in the excerpts. The protein is also known to undergo post-translational modifications, such as glycosylation and phosphorylation, and can exist in different isoforms due to alternative splicing.

## Function
The APOA5 gene encodes apolipoprotein A5, a protein that plays a significant role in lipid metabolism, particularly in the regulation of plasma triglyceride levels. ApoA5 is primarily expressed in the liver and is secreted into the plasma, where it associates with high-density lipoprotein (HDL) and very low-density lipoprotein (VLDL) particles (Schaap2004ApoAV; VuDac2003Apolipoprotein). It modulates triglyceride levels through two main mechanisms: enhancing the catabolism of triglyceride-rich lipoproteins and inhibiting the production rate of VLDL (Garelnabi2013The). ApoA5 enhances lipoprotein lipase (LPL) activity, which is crucial for the hydrolysis of triglycerides, thereby promoting the clearance of triglyceride-rich lipoproteins from the bloodstream (Schaap2004ApoAV).

In cellular processes, apoA5 is internalized by adipocytes and associates with lipid droplets, reducing triglyceride accumulation and potentially limiting adipocyte enlargement (Zheng2012Apolipoprotein). It also influences intracellular triglyceride metabolism by enhancing lipolysis and energy expenditure, mediated by low-density lipoprotein receptor protein 1 (LRP1) (Zheng2017Apolipoprotein). These activities contribute to maintaining normal triglyceride levels and lipid homeostasis in healthy human cells (VuDac2003Apolipoprotein).

## Clinical Significance
Mutations in the APOA5 gene are associated with several lipid metabolism disorders, primarily affecting triglyceride levels. Severe hypertriglyceridemia (HTG) is a notable condition linked to APOA5 mutations, such as the Q97X mutation, which results in a truncated, non-functional protein. This mutation has been identified in a Chilean consanguineous family, where affected individuals exhibit elevated triglyceride levels and are at risk for acute pancreatitis (Dussaillant2012APOA5). Other mutations, including Q148X, Q139X, and IVS3+3G>C, are also associated with severe chylomicronemia, a condition characterized by the accumulation of chylomicrons in the blood (Dussaillant2012APOA5).

The APOA5 p.S19W variant is linked to increased triglyceride levels and is considered a risk factor for coronary artery disease (CAD). This variant is more frequent in CAD patients and is associated with higher triglyceride levels, suggesting its significant role in triglyceride metabolism and cardiovascular risk (Soufi2012Mutation).

Rare mutations, such as the c427delC, p.Arg143Alafs*57, lead to severe HTG and recurrent pancreatitis. These mutations result in a truncated protein that cannot effectively interact with lipoprotein lipase, impairing triglyceride hydrolysis (Makhmudova2024Monogenic). The management of these conditions often involves dietary modifications and pharmacological interventions, highlighting the clinical significance of APOA5 in lipid disorders (Thériault2016Frameshift).

## Interactions
Apolipoprotein A5 (APOA5) is involved in several key interactions that influence triglyceride metabolism. One significant interaction is with the ANGPTL3/8 complex in human serum. APOA5 binds to this complex, which is known to inhibit lipoprotein lipase (LPL), an enzyme crucial for triglyceride hydrolysis. By associating with the ANGPTL3/8 complex, APOA5 suppresses its inhibitory effect on LPL, thereby promoting triglyceride breakdown (Chen2021ApoA5).

The binding of APOA5 to the ANGPTL3/8 complex is characterized by a high affinity, with a very slow dissociation rate, indicating a stable interaction. This interaction is specific, as APOA5 does not affect the LPL-inhibitory activities of other ANGPTL proteins such as ANGPTL3, ANGPTL4, or the ANGPTL4/8 complex (Chen2021ApoA5).

APOA5's interaction with the ANGPTL3/8 complex is also influenced by insulin, which modulates the secretion of these proteins. Insulin increases ANGPTL8 secretion, forming a complex with ANGPTL3 that inhibits LPL in skeletal muscle but not in adipose tissue, suggesting a role for APOA5 in directing fatty acid uptake postprandially (Chen2021ApoA5).


## References


[1. (Soufi2012Mutation) Muhidien Soufi, Alexander M. Sattler, Bilgen Kurt, and Juergen R. Schaefer. Mutation screening of the apoa5 gene in subjects with coronary artery disease. Journal of Investigative Medicine, 60(7):1015–1019, October 2012. URL: http://dx.doi.org/10.2310/JIM.0b013e3182686918, doi:10.2310/jim.0b013e3182686918. This article has 24 citations and is from a peer-reviewed journal.](https://doi.org/10.2310/JIM.0b013e3182686918)

[2. (Zheng2012Apolipoprotein) Xiao-Yan Zheng, Shui-Ping Zhao, Bi-Lian Yu, Chen-Lu Wu, and Ling Liu. Apolipoprotein a5 internalized by human adipocytes modulates cellular triglyceride content. bchm, 393(3):161–167, March 2012. URL: http://dx.doi.org/10.1515/hsz-2011-0259, doi:10.1515/hsz-2011-0259. This article has 25 citations.](https://doi.org/10.1515/hsz-2011-0259)

[3. (Schaap2004ApoAV) Frank G. Schaap, Patrick C.N. Rensen, Peter J. Voshol, Carlos Vrins, Hendrik N. van der Vliet, Robert A.F.M. Chamuleau, Louis M. Havekes, Albert K. Groen, and Ko Willems van Dijk. Apoav reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (vldl-tg) production and stimulating lipoprotein lipase-mediated vldl-tg hydrolysis. Journal of Biological Chemistry, 279(27):27941–27947, July 2004. URL: http://dx.doi.org/10.1074/jbc.m403240200, doi:10.1074/jbc.m403240200. This article has 245 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m403240200)

[4. (Alborn2006Definitive) William E Alborn, Melvin G Johnson, Melvin J Prince, and Robert J Konrad. Definitive n-terminal protein sequence and further characterization of the novel apolipoprotein a5 in human serum. Clinical Chemistry, 52(3):514–517, March 2006. URL: http://dx.doi.org/10.1373/CLINCHEM.2005.061374, doi:10.1373/clinchem.2005.061374. This article has 52 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1373/CLINCHEM.2005.061374)

[5. (Zheng2017Apolipoprotein) Xiao-Yan Zheng, Bi-Lian Yu, Yu-Fei Xie, Shui-Ping Zhao, and Chen-Lu Wu. Apolipoprotein a5 regulates intracellular triglyceride metabolism in adipocytes. Molecular Medicine Reports, 16(5):6771–6779, May 2017. URL: http://dx.doi.org/10.3892/mmr.2017.7461, doi:10.3892/mmr.2017.7461. This article has 18 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2017.7461)

[6. (Garelnabi2013The) Mahdi Garelnabi, Kenton Lor, Jun Jin, Fei Chai, and Nalini Santanam. The paradox of apoa5 modulation of triglycerides: evidence from clinical and basic research. Clinical Biochemistry, 46(1–2):12–19, January 2013. URL: http://dx.doi.org/10.1016/j.clinbiochem.2012.09.007, doi:10.1016/j.clinbiochem.2012.09.007. This article has 55 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.clinbiochem.2012.09.007)

[7. (Castleberry2020Functional) Mark Castleberry, Xenia Davis, Min Liu, Thomas B. Thompson, Patrick Tso, and W. Sean Davidson. Functional recombinant apolipoprotein a5 that is stable at high concentrations at physiological ph. Journal of Lipid Research, 61(2):244–251, February 2020. URL: http://dx.doi.org/10.1194/jlr.d119000103, doi:10.1194/jlr.d119000103. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1194/jlr.d119000103)

[8. (Thériault2016Frameshift) Sébastien Thériault, Andrew Don-Wauchope, Michael Chong, Ricky Lali, Katherine M. Morrison, and Guillaume Paré. Frameshift mutation in the apoa5 gene causing hypertriglyceridemia in a pakistani family: management and considerations for cardiovascular risk. Journal of Clinical Lipidology, 10(5):1272–1277, September 2016. URL: http://dx.doi.org/10.1016/j.jacl.2016.07.009, doi:10.1016/j.jacl.2016.07.009. This article has 6 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jacl.2016.07.009)

[9. (Chen2021ApoA5) Yan Q. Chen, Thomas G. Pottanat, Eugene Y. Zhen, Robert W. Siegel, Mariam Ehsani, Yue-Wei Qian, and Robert J. Konrad. Apoa5 lowers triglyceride levels via suppression of angptl3/8-mediated lpl inhibition. Journal of Lipid Research, 62:100068, 2021. URL: http://dx.doi.org/10.1016/j.jlr.2021.100068, doi:10.1016/j.jlr.2021.100068. This article has 51 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.jlr.2021.100068)

[10. (VuDac2003Apolipoprotein) Ngoc Vu-Dac, Philippe Gervois, Heidi Jakel, Maxime Nowak, Eric Baugé, Hélène Dehondt, Bart Staels, Len A. Pennacchio, Edward M. Rubin, Jamila Fruchart-Najib, and Jean-Charles Fruchart. Apolipoprotein a5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor α activators. Journal of Biological Chemistry, 278(20):17982–17985, May 2003. URL: http://dx.doi.org/10.1074/jbc.M212191200, doi:10.1074/jbc.m212191200. This article has 293 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.M212191200)

[11. (Makhmudova2024Monogenic) Umidakhon Makhmudova, P. Christian Schulze, Stefan Lorkowski, Winfried März, J.-A. Geiling, and Oliver Weingärtner. Monogenic hypertriglyceridemia and recurrent pancreatitis in a homozygous carrier of a rare apoa5 mutation: a case report. Journal of Medical Case Reports, June 2024. URL: http://dx.doi.org/10.1186/s13256-024-04532-0, doi:10.1186/s13256-024-04532-0. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13256-024-04532-0)

[12. (Dussaillant2012APOA5) Catalina Dussaillant, Valentina Serrano, Alberto Maiz, Susana Eyheramendy, Luis Rodrigo Cataldo, Matías Chavez, Susan V Smalley, Marcela Fuentes, Attilio Rigotti, Lorena Rubio, Carlos F Lagos, José Alfredo Martinez, and José Luis Santos. Apoa5 q97x mutation identified through homozygosity mapping causes severe hypertriglyceridemia in a chilean consanguineous family. BMC Medical Genetics, November 2012. URL: http://dx.doi.org/10.1186/1471-2350-13-106, doi:10.1186/1471-2350-13-106. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/1471-2350-13-106)